Myriad Genetics (MYGN) Aandelenoverzicht
Myriad Genetics, Inc., een bedrijf voor moleculaire diagnostiek en precisiegeneeskunde, ontwikkelt moleculaire tests. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
MYGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Myriad Genetics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$3.19 |
| 52 Week Hoogtepunt | US$8.59 |
| 52 Week Laag | US$2.74 |
| Bèta | 1.67 |
| 1 maand verandering | -46.11% |
| 3 maanden verandering | -18.41% |
| 1 Jaar Verandering | -42.31% |
| 3 jaar verandering | -82.40% |
| 5 jaar verandering | -90.84% |
| Verandering sinds IPO | -40.65% |
Recent nieuws en updates
Narratiefupdate • Aug 18
MYGN: Turnaround Will Rely On Stabilising Hereditary Cancer And Prenatal Testing
Analysts have cut their fair value estimate for Myriad Genetics from $10.00 to $5.45, reflecting lower price targets in the $3.00 to $4.00 range after the Q2 miss, reduced guidance, and ongoing concerns around execution and testing headwinds. Analyst Commentary Recent Street research on Myriad Genetics points to a reset in expectations after the Q2 update.
Narratiefupdate • Aug 04
MYGN: Q2 Miss And Lower Guide Will Temper Turnaround Expectations
Analysts have trimmed their fair value estimate for Myriad Genetics to $3.00 from $4.00, reflecting updated views on slower revenue growth, modestly lower profit margins, a higher discount rate, and reduced future P/E assumptions following recent Q2 results and guidance updates. Analyst Commentary Recent research updates on Myriad Genetics point to a more cautious stance from several bearish analysts following the Q2 earnings release and guidance changes.Seeking Alpha • Aug 01
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down
Summary Myriad Genetics faces persistent reimbursement and pricing headwinds, despite stable oncology volumes and pipeline momentum, driving margin compression and revenue volatility. Management is executing the Ascend initiative, aiming to optimize the revenue cycle, automate claims, and improve payer engagement, with the potential for margin inflection by 2027 if successful. FY26 revenue guidance is tightened to $770–$790 million, with adjusted EBITDA guidance withdrawn, reflecting near-term uncertainty and limited visibility on operational improvements. I maintain a Hold rating, as the business remains a turnaround story; execution on reimbursement and revenue conversion is critical before upside can be realized. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Aug 18
MYGN: Turnaround Will Rely On Stabilising Hereditary Cancer And Prenatal Testing
Analysts have cut their fair value estimate for Myriad Genetics from $10.00 to $5.45, reflecting lower price targets in the $3.00 to $4.00 range after the Q2 miss, reduced guidance, and ongoing concerns around execution and testing headwinds. Analyst Commentary Recent Street research on Myriad Genetics points to a reset in expectations after the Q2 update.Narratiefupdate • Aug 04
MYGN: Q2 Miss And Lower Guide Will Temper Turnaround Expectations
Analysts have trimmed their fair value estimate for Myriad Genetics to $3.00 from $4.00, reflecting updated views on slower revenue growth, modestly lower profit margins, a higher discount rate, and reduced future P/E assumptions following recent Q2 results and guidance updates. Analyst Commentary Recent research updates on Myriad Genetics point to a more cautious stance from several bearish analysts following the Q2 earnings release and guidance changes.Seeking Alpha • Aug 01
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down
Summary Myriad Genetics faces persistent reimbursement and pricing headwinds, despite stable oncology volumes and pipeline momentum, driving margin compression and revenue volatility. Management is executing the Ascend initiative, aiming to optimize the revenue cycle, automate claims, and improve payer engagement, with the potential for margin inflection by 2027 if successful. FY26 revenue guidance is tightened to $770–$790 million, with adjusted EBITDA guidance withdrawn, reflecting near-term uncertainty and limited visibility on operational improvements. I maintain a Hold rating, as the business remains a turnaround story; execution on reimbursement and revenue conversion is critical before upside can be realized. Read the full article on Seeking Alpha
Narratiefupdate • Jul 09
MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook
Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).Narratiefupdate • Jun 25
MYGN: 2026 Turnaround Will Be Driven By Expanded Cancer Testing Reach
Analysts have trimmed their target on Myriad Genetics stock by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Myriad Genetics Expanded availability of the Precise MRD test to patients with breast, colorectal, and renal cancers in the U.S., targeting a population of more than 6 million individuals and providing personalized, whole genome sequencing based ctDNA monitoring across the cancer care continuum.Narratiefupdate • Jun 08
MYGN: 2026 Revenue Outlook And Lowered Multiple Will Pressure Sentiment
Analysts have modestly reduced their price target on Myriad Genetics by $1, citing updated assumptions around revenue growth, profitability and future P/E multiples reflected in recent research, including the TD Cowen report. What's in the News Myriad plans to present extensive data on its Precise MRD test across multiple solid tumor types, including interim outcomes from the MONSTAR-SCREEN-3 study.Narratiefupdate • May 25
MYGN: 2026 Turnaround Execution And Cancer Testing Expansion Will Drive Upside
The analyst price target for Myriad Genetics has been reset from $16.06 to $10.00 as analysts factor in lower Street targets around $6, updated assumptions for revenue growth and profit margins, and a revised future P/E closer to 6.3x. Analyst Commentary Recent Street research has generally moved toward more cautious price targets around US$6, but there are still some constructive signals that matter if you are looking at Myriad Genetics through a valuation and execution lens.Narratiefupdate • Apr 21
MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious
Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.Narratiefupdate • Apr 05
MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution
Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.Narratiefupdate • Mar 21
MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment
The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.Narratiefupdate • Mar 06
MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook
Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.Narratiefupdate • Feb 19
MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential
Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.Analyse-artikel • Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...Narratiefupdate • Feb 05
MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook
Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.Analyse-artikel • Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narratiefupdate • Jan 22
MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside
Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.Narratiefupdate • Jan 08
MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook
Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.Narratiefupdate • Dec 24
MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook
Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.Narratiefupdate • Dec 10
MYGN: Improved Earnings Visibility Will Shape Bullish Outlook
Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.Narratiefupdate • Nov 26
MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook
Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.Narratiefupdate • Nov 12
MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains
Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.Narratiefupdate • Oct 29
Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress
Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.Narratiefupdate • Oct 14
Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach
Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).Analyse-artikel • Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...Analyse-artikel • Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...Analyse-artikel • Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...Analyse-artikel • May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
Nieuw narratief • Mar 24
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.Analyse-artikel • Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...Analyse-artikel • Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...Rendement voor aandeelhouders
| MYGN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -1.2% | 6.2% | -0.8% |
| 1Y | -42.3% | 46.3% | 20.5% |
Rendement versus industrie: MYGN presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 46.3 % opleverde.
Rendement versus markt: MYGN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.5 % opleverde.
Prijsvolatiliteit
| MYGN volatility | |
|---|---|
| MYGN Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van MYGN is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MYGN is het afgelopen jaar gestegen van 11% naar 16%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1991 | 2,700 | Sam Raha | www.myriad.com |
Myriad Genetics, Inc., een bedrijf voor moleculaire diagnostiek en precisiegeneeskunde, ontwikkelt moleculaire tests. Het bedrijf biedt moleculaire diagnostische tests aan voor oncologie, vrouwengeneeskunde en farmacogenomica. Het bedrijf biedt ook MyRisk Hereditary Cancer-test, een DNA-sequentietest voor erfelijke kankers; BRACAnalysis CDx Germline Companion Diagnostic-test, een DNA-sequentietest voor gemetastaseerde borst-, eierstok-, gemetastaseerde pancreas- en gemetastaseerde prostaatkanker met schadelijke of vermoedelijk schadelijke germline BRCA-varianten; en MyChoice CDx Companion Diagnostic-test, een tumortest die de homologe recombinatiedeficiëntiestatus bepaalt bij patiënten met eierstokkanker.
Myriad Genetics, Inc. Samenvatting
| MYGN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$274.51m |
| Inkomsten(TTM) | -US$112.60m |
| Inkomsten(TTM) | US$806.60m |
0.4x
P/S-verhouding-2.7x
Koers/WinstverhoudingIs MYGN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MYGN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$806.60m |
| Kosten van inkomsten | US$251.40m |
| Brutowinst | US$555.20m |
| Overige uitgaven | US$667.80m |
| Inkomsten | -US$112.60m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.18 |
| Brutomarge | 68.83% |
| Nettowinstmarge | -13.96% |
| Schuld/Eigen Vermogen Verhouding | 39.7% |
Hoe presteerde MYGN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/19 20:39 |
| Aandelenkoers aan het einde van de dag | 2026/08/19 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Myriad Genetics, Inc. wordt gevolgd door 37 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |